Investment by Ipsen to come on heels of launch of €52m upgraded plant for manufacture of crucial treatments for patients with rare and life-limiting conditions.
Pharma giant Ipsen is planning a further €15m of capital investment in its Blanchardstown site between 2023 and 2026, the company revealed.
Ipsen today (26 September) official opens a newly upgraded manufacturing site following an investment of €52m.
“The Irish market plays an important role as part of Ipsen’s international network and Ipsen is committed to continued investment and innovation in Ireland to support improved care for patients across the therapeutic areas we serve”
The investment has supported the extension and acceleration of vital medicine production which helps patients suffering from both niche cancers and rare diseases in Ireland and across international markets.
Med in Ireland
Ipsen has revealed that a further €15m investment is plan to facilitate continued site enhancement from a technology and sustainability perspective.
Ipsen CEO David Loew said the additional investment is part of Ipsen’s ongoing growth strategy for the Irish market as a biopharmaceutical leader providing transformative care across oncology, rare diseases and neuroscience.
“The Irish market plays an important role as part of Ipsen’s international network and Ipsen is committed to continued investment and innovation in Ireland to support improved care for patients across the therapeutic areas we serve – oncology, rare disease, and neuroscience,” Loew said.
“This new investment in Dublin is a milestone in our ongoing journey of innovation and our growing footprint in Ireland. We hope to continue building Ipsen Ireland as an important pharmaceutical manufacturing and development site within Europe. Now we welcome the continued efforts of the Irish Government to invest in the innovative medicines that will enable Ipsen Ireland to transform even more patients’ lives.”
In addition to its site upgrade, Ipsen said it is committed to supporting and building its team of 175 employees in Ireland working across research & development (R&D), manufacturing and commercial operations, to deliver specialty care APIs for patients with rare and underserved conditions.
“We’re proud of the significant impact our manufacturing improvements have already delivered with our treatment output growing by approximately 10% this year compared to last year,” said Tim Shanahan, general manager and vice-president of Manufacturing for Ipsen Ireland.
“Our team of 175 employees here in Dublin are committed to producing life-enhancing care for patients with rare and underserved medical conditions. It’s great that continued investment in our Irish site is enabling our dedicated team to manufacture at pace and scale to help even more patients in need – not only here in Ireland but in various markets across the world.”
The company has expanded its Blanchardstown workforce by 20% since 2019 and is focused on driving continued research and innovation through its R&D division – growing its team of chemists and analysts by 10% over the past two years.
“I very much welcome Ipsen Ireland’s upgraded manufacturing site in Blanchardstown,” said , Tánaiste Leo Varadkar, TD.
“The company has made a significant investment in this facility which produces treatments for patients with rare and life-limiting conditions. It’s great to see a biopharmaceutical company which has been here for over 30 years continuing to invest and grow in Ireland, particularly when the goal is to help more patients achieve a better quality of life through its medicines.
“Ireland is a world hub for life sciences and we’ve worked hard to create a welcoming environment for companies. We also want to be a global leader in innovation. This approach has helped the Government to attract numerous significant investments and it means that Ireland is well-positioned to attract more jobs in the future.”